-sparing , meaning it avoids many common side effects like weight gain and fluid retention. Core Pharmacology and Mechanism
MSDC-0160 works by selectively binding to and inhibiting the , a protein complex in the inner mitochondrial membrane.
In preclinical models, MSDC-0160 protected dopaminergic neurons, improved motor function, and reduced neuroinflammation. msdc 0160 buy
This forced "metabolic shift" encourages cells to use alternative fuel sources like ketones and fatty acids through -oxidation.
MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR -sparing , meaning it avoids many common side
It blocks the entry of pyruvate into the mitochondria, the main gateway for carbohydrate metabolism.
By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications This forced "metabolic shift" encourages cells to use
It may prevent or reverse dyskinesia (involuntary movements) caused by standard Parkinson's medications. 2. Alzheimer’s Disease (AD) MSDC-0160 - Metabolic Solutions Development Company